Want to see BOLT full AI Analyst Report?
BOLT Stock Chart & Stats
$4.73
-$0.02(-3.16%)
At close: 4:00 PM EST
$4.73
-$0.02(-3.16%)
Day’s Range― - ―
52-Week Range$3.75 - $7.20
Previous CloseN/A
Volume72.19K
Average Volume (3M)29.18K
Market Cap
$8.49M
Enterprise Value$6.00
Total Cash (Recent Filing)$22.89M
Total Debt (Recent Filing)$22.31M
Price to Earnings (P/E)―
Beta0.36
Next Earnings
Aug 12, 2026EPS Estimate
-3.39Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-15.89
Shares Outstanding1,921,567
10 Day Avg. Volume31,146
30 Day Avg. Volume29,181
Financial Highlights & Ratios
PEG Ratio>-0.01
Price to Book (P/B)0.39
Price to Sales (P/S)1.33
P/FCF Ratio-0.26
Enterprise Value/Market Cap<0.01
Enterprise Value/Revenue<0.01
Enterprise Value/Gross Profit<0.01
Enterprise Value/Ebitda>-0.01
Forecast
1Y Price Target
$34.67Price Target Upside632.91% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering4
EPS Forecast (FY)-14.43
Revenue Forecast (FY)$1.51M
Bulls Say, Bears Say
Bulls Say
Proprietary Boltbody PlatformBolt's Boltbody platform represents a structural, technology-led advantage: directing immune activation in the tumor microenvironment can differentiate therapies, enable multiple candidates from one platform, and increase long-term partnership and licensing optionality if clinical validation occurs, supporting durable value creation.
Improved Gross Margins RecentlyAn uptick in gross margin is a durable operational improvement that can reduce required cash per unit of revenue as programs progress. For a clinical-stage biotech, stronger gross margins indicate tighter cost control or favorable program economics, which supports sustainability of operations and limits future dilution pressure once revenues scale.
Governance Continuity And Auditor RatificationStable board composition and retention of a reputable auditor provide continuity in oversight and financial reporting. This lowers execution and compliance risk over the medium term, helping maintain investor and partner confidence as the company advances clinical programs and seeks collaborations or financing.
Bears Say
Very Small, Declining RevenueTTM revenue is minimal and falling, reflecting reliance on episodic collaboration income rather than product sales. This structural revenue weakness limits internal funding for trials, reduces negotiating leverage with partners, and prolongs dependence on external financing, affecting the company's ability to self-fund development over months.
Persistent Negative Free Cash FlowConsistent cash burn and deteriorating free cash flow require repeated capital raises or partner funding. For a clinical-stage biotech, this structural cash shortfall increases dilution risk, can delay or curtail trials if funding lags, and constrains strategic flexibility over the 2–6 month horizon and beyond.
Rising Leverage And Shrinking EquityIncreasing leverage and declining equity reduce balance-sheet resilience. Higher debt-to-equity raises refinancing and interest risks, limits capacity to absorb setbacks, and may restrict ability to make opportunistic investments or secure favorable partnership terms—material constraints for a development-stage company.
Bolt Biotherapeutics News
BOLT FAQ
What was Bolt Biotherapeutics’s price range in the past 12 months?
Bolt Biotherapeutics lowest stock price was $3.75 and its highest was $7.20 in the past 12 months.
What is Bolt Biotherapeutics’s market cap?
Bolt Biotherapeutics’s market cap is $8.49M.
When is Bolt Biotherapeutics’s upcoming earnings report date?
Bolt Biotherapeutics’s upcoming earnings report date is Aug 12, 2026 which is in 23 days.
How were Bolt Biotherapeutics’s earnings last quarter?
Bolt Biotherapeutics released its earnings results on May 12, 2026. The company reported -$4.31 earnings per share for the quarter, missing the consensus estimate of -$2.85 by -$1.46.
Is Bolt Biotherapeutics overvalued?
According to Wall Street analysts Bolt Biotherapeutics’s price is currently Undervalued.
Does Bolt Biotherapeutics pay dividends?
Bolt Biotherapeutics pays a Quarterly dividend of $0.09 which represents an annual dividend yield of N/A. See more information on Bolt Biotherapeutics dividends here
What is Bolt Biotherapeutics’s EPS estimate?
Bolt Biotherapeutics’s EPS estimate is -3.39.
How many shares outstanding does Bolt Biotherapeutics have?
Bolt Biotherapeutics has 1,921,567 shares outstanding.
What happened to Bolt Biotherapeutics’s price movement after its last earnings report?
Bolt Biotherapeutics reported an EPS of -$4.31 in its last earnings report, missing expectations of -$2.85. Following the earnings report the stock price went up 1.046%.
Which hedge fund is a major shareholder of Bolt Biotherapeutics?
Currently, no hedge funds are holding shares in BOLT
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Bolt Biotherapeutics
Bolt Biotherapeutics, Inc. is a biotechnology company currently conducting clinical trials, focused on developing innovative immuno-oncology therapies. Its mission is to create agents that equip the body's immune system to identify and eliminate cancerous cells. A key therapeutic in its pipeline is BDC-1001, an investigational treatment targeting the human epidermal growth factor receptor 2 (HER2). This compound is presently undergoing Phase I/II clinical evaluation for patients with HER2-positive solid tumors, including those exhibiting low HER2 expression. Beyond BDC-1001, the company is advancing several other programs: BDC-2034, which targets carcinoembryonic antigen for various indications such as colorectal, non-small cell lung, pancreatic, and breast cancers; and BDC-3042, a Dectin-2 agonist antibody designed to reprogram crucial immune cells within the tumor microenvironment by interacting with macrophage cell-surface receptors. Bolt is also pursuing a programmed cell death-ligand 1 (PD-L1) initiative aimed at addressing tumors that prove resistant to existing immune checkpoint blockades. Incorporated in 2015 under its previous name, Bolt Therapeutics, Inc., before officially becoming Bolt Biotherapeutics, Inc. in July of the same year, the company maintains its corporate headquarters in Redwood City, California.
BOLT Stock 12 Month Forecast
Average Price Target
$34.67
▲(632.91% Upside)
Technical Analysis
Ownership Overview
2.28% Insiders
3.97% Mutual Funds
23.96% Other Institutional Investors
69.42% Public Companies and
Individual Investors